Article
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide.
Journal of hepatology - 1 Nov 2024
Toniutto Pierluigi, Falleti Edmondo, Cmet Sara, Cussigh Annarosa, Degasperi Elisabetta, Anolli Maria Paola, Sambarino Dana, Facchetti Floriana, Borghi Marta, Perbellini Riccardo, Monico Sara, Lampertico Pietro
Abstract excerpt
BACKGROUND & AIMS: Genetic polymorphisms in the sodium taurocholate cotransporting peptide (NTCP encoded by SLC10A1) have been described, but their role in untreated and treated patients with chronic hepatitis delta (CHD) remains unknown. Virological response (VR) to the NTCP inhibitor bulevirtide (BLV) was achieved at week 48 by >70% of patients with CHD, but nearly 15% experienced virological non-response (VNR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
